INmune Bio, Inc. (INMB) Earnings History
Annual and quarterly earnings data from 2015 to 2025
Loading earnings history...
INMB EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
INMB Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 100.0% | -61738.0% | -91866.0% |
| 2024 | 100.0% | -304535.7% | -300585.7% |
| 2023 | 100.0% | -19187.7% | -19360.0% |
| 2022 | 100.0% | -6938.8% | -7299.2% |
| 2021 | 100.0% | -16106.6% | -16762.4% |
Download Data
Export INMB earnings history in CSV or JSON format
Free sign-in required to download data
INmune Bio, Inc. (INMB) Earnings Overview
As of May 8, 2026, INmune Bio, Inc. (INMB) reported trailing twelve-month net income of -$42M, reflecting +11.8% year-over-year growth. The company earned $-1.56 per diluted share over the past four quarters, with a net profit margin of -91866.0%.
Looking at the long-term picture, INMB's historical earnings data spans multiple years. The company achieved its highest annual net income of -$48,868 in fiscal 2015.
INmune Bio, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SAVA (-$106M net income), PRTA (-$151M net income, -2520.6% margin), ACAD ($376M net income, 36.5% margin), INMB has comparable earnings metrics. Compare INMB vs SAVA →
INMB Earnings vs Peers
Earnings metrics vs comparable public companies
INMB Historical Earnings Data (2015–2025)
11 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$46M | -9.2% | -$31M | $-1.86 | -91866.0% | -61738.0% |
| 2024 | -$42M | -40.2% | -$43M | $-2.11 | -300585.7% | -304535.7% |
| 2023 | -$30M | -9.9% | -$30M | $-1.67 | -19360.0% | -19187.7% |
| 2022 | -$27M | +10.0% | -$26M | $-1.52 | -7299.2% | -6938.8% |
| 2021 | -$30M | -150.8% | -$29M | $-1.88 | -16762.4% | -16106.6% |
| 2020 | -$12M | -57.6% | -$12M | $-1.01 | -109990.9% | -111163.6% |
| 2019 | -$8M | +38.3% | -$8M | $-0.89 | - | - |
| 2018 | -$12M | -1397.0% | -$12M | $-1.11 | - | - |
| 2017 | $-831,000 | -200.0% | $-981,000 | $-0.07 | - | - |
| 2016 | $-277,000 | -466.8% | $-227,000 | $-0.05 | - | - |
See INMB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs INMB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare INMB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonINMB — Frequently Asked Questions
Quick answers to the most common questions about buying INMB stock.
Is INMB growing earnings?
INMB EPS stands at $-1.56, with +11.8% growth matching the 5-year CAGR of N/A. TTM net income is $-42M. Earnings trajectory remains consistent.
What are INMB's profit margins?
INmune Bio, Inc. net margin is -91866.0%, with operating margin at -61738.0%. Below-average margins reflect competitive or cost pressures.
How consistent are INMB's earnings?
INMB earnings data spans 2015-2025. The current earnings trend is +11.8% YoY. Historical data enables comparison across business cycles.